These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 8996848)

  • 21. Tests for individual and population bioequivalence based on generalized p-values.
    McNally RJ; Iyer H; Mathew T
    Stat Med; 2003 Jan; 22(1):31-53. PubMed ID: 12486750
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New bioequivalence studies: individual bioequivalence and population bioequivalence.
    Nakai K; Fujita M; Ogata H
    Yakugaku Zasshi; 2000 Nov; 120(11):1201-8. PubMed ID: 11190205
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bioavailability and bioequivalence trials: statistics & pharmacokinetic principles.
    Rajaram L; Roy SK; Skerjanec A
    Stud Health Technol Inform; 2004; 103():159-79. PubMed ID: 15747918
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bioavailability and bioequivalence of two oral formulations of alendronate sodium 70 mg: an open-label, randomized, two-period crossover comparison in healthy Korean adult male volunteers.
    Rhim SY; Park JH; Park YS; Lee MH; Kim DS; Shaw LM; Yang SC; Kang JS
    Clin Ther; 2009 May; 31(5):1037-45. PubMed ID: 19539104
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative crossover, randomized, open-label bioequivalence study on the bioequivalence of two formulations of thioctic acid in healthy volunteers.
    Mignini F; Streccioni V; Tomassoni D; Traini E; Amenta F
    Clin Exp Hypertens; 2007 Nov; 29(8):575-86. PubMed ID: 18058482
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aspects of bioavailability and bioequivalence revision: possible implications on clinical pharmacology.
    Glasser AC
    Methods Find Exp Clin Pharmacol; 1987 Jul; 9(7):449-52. PubMed ID: 3683019
    [No Abstract]   [Full Text] [Related]  

  • 27. The bootstrap in bioequivalence studies.
    Pigeot I; Hauschke D; Shao J
    J Biopharm Stat; 2011 Nov; 21(6):1126-39. PubMed ID: 22023681
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An individual bioequivalence criterion: regulatory considerations.
    Chen ML; Patnaik R; Hauck WW; Schuirmann DJ; Hyslop T; Williams R
    Stat Med; 2000 Oct; 19(20):2821-42. PubMed ID: 11033578
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interchangeability between Generic and Reference Products: Limits of Average Bioequivalence Methodology.
    Lechat P
    Eur J Drug Metab Pharmacokinet; 2022 Nov; 47(6):777-787. PubMed ID: 35986193
    [TBL] [Abstract][Full Text] [Related]  

  • 30. On population and individual bioequivalence.
    Schall R; Luus HG
    Stat Med; 1993 Jun; 12(12):1109-24. PubMed ID: 8210816
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Aspects for bioavailability and bioequivalence revision: possible implications on clinical pharmacology.
    Ritschel WA
    Methods Find Exp Clin Pharmacol; 1987 Jul; 9(7):453-9. PubMed ID: 3683020
    [No Abstract]   [Full Text] [Related]  

  • 32. Kullback-Leibler divergence for evaluating bioequivalence.
    Dragalin V; Fedorov V; Patterson S; Jones B
    Stat Med; 2003 Mar; 22(6):913-30. PubMed ID: 12627409
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessment of selection bias in estimates of relative bioavailability and intrasubject variability from bioequivalence evaluations.
    Wang Y
    J Biopharm Stat; 2000 Aug; 10(3):407-24. PubMed ID: 10959920
    [TBL] [Abstract][Full Text] [Related]  

  • 34. On the bioavailability of oral chondroitin sulfate formulations: proposed criteria for bioequivalence studies.
    Vergés J; Castañeda-Hernández G
    Proc West Pharmacol Soc; 2004; 47():50-3. PubMed ID: 15633611
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro bioequivalence testing.
    Chow SC; Shao J; Wang H
    Stat Med; 2003 Jan; 22(1):55-68. PubMed ID: 12486751
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Statistical evaluation of physiological variability of rifampicin in fixed dose combinations.
    Panchagnula R; Parmar J; Kaur K; Singh I; Bade SR; Ashokraj Y
    Int J Pharm; 2006 Apr; 313(1-2):5-13. PubMed ID: 16517107
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Computer simulations of bioequivalence trials: selection of design and analyte in BCS drugs with first-pass hepatic metabolism: linear kinetics (I).
    Fernández-Teruel C; Nalda Molina R; González-Alvarez I; Navarro-Fontestad C; García-Arieta A; Casabó VG; Bermejo M
    Eur J Pharm Sci; 2009 Jan; 36(1):137-46. PubMed ID: 19028574
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bioequivalence approaches for highly variable drugs and drug products.
    Haidar SH; Davit B; Chen ML; Conner D; Lee L; Li QH; Lionberger R; Makhlouf F; Patel D; Schuirmann DJ; Yu LX
    Pharm Res; 2008 Jan; 25(1):237-41. PubMed ID: 17891552
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bayesian approach to average bioequivalence using Bayes' factor.
    Ghosh P; Khattree R
    J Biopharm Stat; 2003 Nov; 13(4):719-34. PubMed ID: 14584718
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Critical considerations into the new EMA guideline on bioequivalence.
    Marzo A; Fontana E
    Arzneimittelforschung; 2011; 61(4):207-20. PubMed ID: 21650079
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.